Baseline demographics and disease characteristics
| Characteristic . | Cohort A (BV naive) (n = 63) . | Cohort B (BV after auto-HCT) (n = 80) . | Cohort C (BV before and/or after auto-HCT) (n = 100) . | Overall (N = 243) . |
|---|---|---|---|---|
| Age, median (range), y | 33 (18-65) | 37 (18-72) | 32 (19-69) | 34 (18-72) |
| Female, n (%) | 29 (46.0) | 29 (36.3) | 44 (44.0) | 102 (42.0) |
| Stage at study entry, n (%) | ||||
| I | 1 (1.6) | 1 (1.3) | 2 (2.0) | 4 (1.6) |
| II | 19 (30.2) | 11 (13.8) | 20 (20.0) | 50 (20.6) |
| III | 18 (28.6) | 14 (17.5) | 17 (17.0) | 49 (20.2) |
| IV | 24 (38.1) | 54 (67.5) | 61 (61.0) | 139 (57.2) |
| Not reported | 1 (1.6) | 0 | 0 | 1 (0.4) |
| B symptoms at study entry, n (%) | 10 (15.9) | 18 (22.5) | 25 (25.0) | 53 (21.8) |
| Bulky disease at study entry, n (%) | 10 (15.9) | 17 (21.3) | 22 (22.0) | 49 (20.2) |
| Extralymphatic involvement, n (%) | 24 (38.1) | 36 (45.0) | 45 (45.0) | 105 (43.2) |
| Median prior lines of therapy (IQR) | 2 (2-3) | 4 (4-7) | 4 (3-5) | 4 (3-5) |
| Time from diagnosis to first dose of nivolumab, median (IQR), y | 3.1 (2.0-7.5) | 6.2 (3.3-8.3) | 3.5 (2.3-6.4) | 4.5 (2.4-7.6) |
| Characteristic . | Cohort A (BV naive) (n = 63) . | Cohort B (BV after auto-HCT) (n = 80) . | Cohort C (BV before and/or after auto-HCT) (n = 100) . | Overall (N = 243) . |
|---|---|---|---|---|
| Age, median (range), y | 33 (18-65) | 37 (18-72) | 32 (19-69) | 34 (18-72) |
| Female, n (%) | 29 (46.0) | 29 (36.3) | 44 (44.0) | 102 (42.0) |
| Stage at study entry, n (%) | ||||
| I | 1 (1.6) | 1 (1.3) | 2 (2.0) | 4 (1.6) |
| II | 19 (30.2) | 11 (13.8) | 20 (20.0) | 50 (20.6) |
| III | 18 (28.6) | 14 (17.5) | 17 (17.0) | 49 (20.2) |
| IV | 24 (38.1) | 54 (67.5) | 61 (61.0) | 139 (57.2) |
| Not reported | 1 (1.6) | 0 | 0 | 1 (0.4) |
| B symptoms at study entry, n (%) | 10 (15.9) | 18 (22.5) | 25 (25.0) | 53 (21.8) |
| Bulky disease at study entry, n (%) | 10 (15.9) | 17 (21.3) | 22 (22.0) | 49 (20.2) |
| Extralymphatic involvement, n (%) | 24 (38.1) | 36 (45.0) | 45 (45.0) | 105 (43.2) |
| Median prior lines of therapy (IQR) | 2 (2-3) | 4 (4-7) | 4 (3-5) | 4 (3-5) |
| Time from diagnosis to first dose of nivolumab, median (IQR), y | 3.1 (2.0-7.5) | 6.2 (3.3-8.3) | 3.5 (2.3-6.4) | 4.5 (2.4-7.6) |
IQR, interquartile range.